KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $1.7 billion.

  • Alnylam Pharmaceuticals' Cash & Equivalents rose 7148.2% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 7148.2%. This contributed to the annual value of $1.7 billion for FY2025, which is 7148.2% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Cash & Equivalents stood at $1.7 billion, which was up 7148.2% from $1.5 billion recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Cash & Equivalents peaked at $1.7 billion during Q4 2025, and registered a low of $379.5 million during Q1 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Cash & Equivalents had a median value of $917.5 million in 2022 and averaged $913.3 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Cash & Equivalents skyrocketed by 12025.01% in 2021, and later tumbled by 2282.33% in 2022.
  • Alnylam Pharmaceuticals' Cash & Equivalents (Quarter) stood at $822.2 million in 2021, then rose by 5.64% to $868.6 million in 2022, then fell by 6.43% to $812.7 million in 2023, then grew by 18.92% to $966.4 million in 2024, then surged by 71.48% to $1.7 billion in 2025.
  • Its Cash & Equivalents was $1.7 billion in Q4 2025, compared to $1.5 billion in Q3 2025 and $1.1 billion in Q2 2025.